Merck at peer perform by Bear Stearns

Bear Stearns analyst John Boris rated Merck & Co. Inc. at peer perform and maintained his global Januvia franchise revenue estimate of $1.8 billion by 2012. The analyst expects Januvia to account for roughly one-third of Merck's five-year (2006-2011) incremental revenue of $4.1 billion. Januvia's U.S. launch is imminent with no label surprises, according to the analyst. Shares of the Whitehouse Station, N.J., pharmaceutical company were up 52 cents, or 1.18%, at $44.48. (NYSE: MRK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.